ICNMDigital Program

Session Chair: Prof Marianne De Visser, The Netherlands

Inflammatory Autoimmune Myopathies
Prof Olivier Benaviste, France
30 Minutes

Genetic Therapies
Dr Kevin Flanigan, United States
30 minutes

Session Chair: Prof Bjarne Udd, Finland

MYO-SEQ, Diagnosing Patients with LGMD
Prof Volker Straub, UK
30 minutes

Metabolic Therapies
Prof John Vissing, Denmark
30 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Antonio Tascano, Italy

Novel Image Analysis to Assess Molecular Functionality of Dystrophin in Duchenne Muscular Dystrophy Clinical Trials
Mr Dominic Scaglioni, UK
20 minutes

A Dominant PYGM Mutation Causes a New Class of Glycogen Storage Diseases
Dr Jocelyn Laporte, France
20 minutes

Therapeutic potential of antagomiR-23b for treating Myotonic Dystrophy
Sra Beatriz Llamusi, Spain
20 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Peter Van Den Bergh, Belgium

Dysimmune Nodo-Paranodopathies
Dr Luis Querol, Spain
30 minutes

Painful Channelopathies
Prof Giuseppe Lauria, Italy
30 minutes

Session Chair: Dr Davide Pareyson, Italy

Charcot-Marie-Tooth and Related Neuropathies
Prof Mary Reilly, UK
30 minutes

Diabetic Neuropathy: Treatment and Costs
Dr Brian Callaghan, USA
30 minutes

Sponsored Symposium
60 minutes

Sessions Chair: Prof John England, USA

Combination of RNA-Interference and Gene Therapy to Treat Charcot-Marie-Tooth Type 2A
Dr Elena Abati, Italy
20 minutes

PDXK-Related Peripheral Neuropathy With Optic Atrophy. A New Treatable Disease
Dr Viorica Chelban, United Kingdom
20 minutes

De Novo Variants in POLR3B Cause Demyelinating Neuropathy, Ataxia, and Spasticity
Dr Djurdja Djordjevic, Canada
20 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Zohar Argov, Israel

Congenital Myasthenic Syndromes
Prof David Beeson, United Kingdom
30 minutes

Thymectomy
Dr Gil Wolfe, United States
30 minutes

Session Chair: Prof Angela Vincent, UK

Immunoactive Drug Therapy
Prof Nils Erik Gilhus, Norway
30 minutes

Drugs Related Exacerbation
Amelia Evoli, Italy
30 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Susana Quijano-Roy, France

Clinical Characteristics and Outcomes of Thymoma Associated Myasthenia Gravis
Mr Rodrigo Alvarez Velasco, Spain
20 minutes

Treatment Impact on Specific Symptom MG-ADL Domains Myasthenia Gravis Patients: Phase 2 Efgartigimod Study Analysis
Dr James Howard, United States
20 minutes

Prevalence and Associated Factors of Fatigue in the Dutch MG Population
Dr Martijn Tannemaat, Netherlands
20 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Marianne De Visser, The Netherlands

New guidelines For the Design and Implementation of ALS Clinical Trials
Prof Leonard Van Den Berg, Netherlands
30 minutes

Advances in Genetics & Epigenetic of ALS
Dr Bryan Traynor, United States
30 minutes

Session Chair: Prof Benedikt Schoser, Germany

Therapeutic Considerations in SMA 2020: Who, When and How to Treat
Dr Richard Finkel, United States
30 minutes

Newborn Screening
Prof Laurent Servais, UK
30 minutes

Sponsored Symposium
60 minutes

Session Chair: Prof Enrico Bertini, Italy

A Longitudinal Natural History Study for Type 2 and 3 Spinal Muscle Atrophy
Ms Jesica Maria Exposito Escudero, Spain
20 minutes

TDP-43 Nucleo-Cytoplasmic Mislocalization Can be Rescued by Antisense Oligonucleotide Treatment in C9Orf72-Related ALS Cell Lines
Dr Delia Gagliardi, Italy
20 minutes

Cervical Spinal Cord Atrophy: An Early Marker of Survival Time in Amyotrophic Lateral Sclerosis
Miss Virginia Reyes Garrido, Spain
20 minutes

Sponsored Symposium
60 minutes